BIOR Jul 2024 1.000 call
| Previous Close | 0.0900 |
| Open | 0.1000 |
| Bid | 0.0000 |
| Ask | 0.0000 |
| Strike | 1.00 |
| Expire Date | 2024-07-19 |
| Day's Range | 0.0900 - 0.1000 |
| Contract Range | N/A |
| Volume | |
| Open Interest | 2.34k |
GlobeNewswireBiora Therapeutics Presents Clinical Data on Device Function of the NaviCap™ Platform at Digestive Disease Week 2024
Four clinical device performance studies successfully demonstrate the NaviCap platform’s ability to deliver therapeutics directly to the colon under variable GI conditions and eating schedulesSAN DIEGO, May 20, 2024 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company that is reimagining therapeutic delivery, presented a poster titled “Results of human device function studies for the NaviCap™ Targeted Oral Delivery Platform in healthy volunteers and patients with UC”
- GuruFocus.com
Biora Therapeutics Inc (BIOR) Q1 2024 Earnings Call Transcript Highlights: Navigating Through ...
Explore key financial outcomes, strategic advancements, and expert insights from Biora Therapeutics' first quarter earnings discussion.
- GlobeNewswire
Biora Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial Results
Dosing of all patients in clinical trial of BT-600 has been successfully completed, with results anticipated in late Q2 2024 Clinical data on device function of the NaviCap™ platform to be presented at DDW on May 19 Partnering process for the BioJet oral delivery platform is progressing well Management will host conference call and webcast today at 4:30 PM Eastern / 1:30 PM Pacific SAN DIEGO, May 15, 2024 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company that is re
